Stage 4 Pancreatic Cancer Prognosis Treatment
Alternative Pancreatic Cancer Treatments Designed to Provide Options for Inoperable Tumors
In the current medical landscape, pancreatic cancer is one of the most difficult and complicated cancers to treat. Patients who are diagnosed often face a late-stage, metastatic pancreatic cancer prognosis that limits their viable treatment options. While the Whipple procedure can be potentially lifesaving for early-stage pancreatic cancer patients, oftentimes the disease has spread too much to make it a viable option in late-stage cancer patients. Integrative Cancer Centers of America recognizes the obstacles patients face when treating stage IV pancreatic cancer which is why we have invested our resources into creating an innovative treatment procedure to potentially improve a patient's chance of seeing positive outcomes.
Chemo Immunotherapy Percutaneous Injection
CIPI ™, short for Chemo Immunotherapy Percutaneous Injection, is a form of precision tumor chemoembolization that combines genetically driven medications with a minimally invasive and highly accurate procedure to target pancreatic cancer patients' inoperable tumors. As one of the world's leading integrative clinics, we at ICCA are constantly working to improve our treatment methods so we can provide our patients with the latest research-based options. We believe that CIPI ™ is an important component to the future of pancreatic cancer treatment as a whole and we hope that CIPI ™ can make a substantial difference in the treatment of advanced stage pancreatic cancer.
CIPI ™ is a minimally invasive targeted procedure that was established to offer a viable alternative to traditional pancreatic cancer treatment options. The procedure was created out of necessity because pancreatic cancer patients represent a portion of the cancer community that often have few avenues for effective treatment of their disease. There are several factors that reduce the effectiveness of treatment for pancreatic cancer patients which are important to discuss.
Pancreatic Cancer Treatment Limiting Factors
It is common for patients to receive a diagnosis in the later metastasized stages of the disease. The combination of a late or missed diagnosis along with the pancreas's location and proximity to other organs often makes surgery an unavailable option for most pancreatic cancer patients. Also, with a 20% one-year survival rate and about 7% five-year survival rate , traditional intravenous chemotherapy has proven largely ineffective against pancreatic cancer. This low survival rate is largely due to the pancreas's stroma which acts as a protective barrier preventing most chemotherapies from being absorbed into the cancerous tumors. These hurdles to care have made pancreatic cancer a truly complex condition to treat. Fortunately, at Integrative Cancer Centers of America, we believe that the CIPI ™ procedure could be helpful for end-stage pancreatic cancer patients who do not have viable options available to them.
Integrative Cancer Centers of America designed CIPI ™ as a form of minimally invasive targeted tumor chemoembolization, using specialized genetic targets and a proprietary treatment plan, CIPI's goal is to directly ablate the cancerous mass while encouraging a systemic immunotherapy response with precision and personalization for each patient. Because patients often have inoperable pancreatic cancer, CIPI ™ uses a minimally invasive microcatheter that is about the width of a human hair, that is placed into the arterial blood supply that leads to the tumor and fed through the body right up to the cancerous mass. Once the microcatheter has reached the tumor, ICCA deploys multiple treatments comprising of genetically targeted chemotherapy, immunotherapy, and chemo adjunctive agents, to be placed in sequence directly inside the cancerous tumor to potentially improve direct tumor kill while helping turn on the body's own immune system to fight the metastatic cancer throughout the body.
Next, a set of dissolvable beads are placed in the blood vessel sealing the agents inside the tumor, allowing the genetically targeted agents to make their way through the cancerous mass to necrose or embolize the tumor. As the tumor necroses, it releases antigens with important immunological information that may allow the immune system to recognize metastasized cancerous cells throughout the body. The antigens are picked up by dendritic cells, where the immunological information is processed and then delivered to natural killer cells. The NK cells use this information to help locate and attack other metastatic cancerous cells in the body, creating a systemic response throughout the body wherever those antigens are present. The procedure is minimally invasive, and as the catheter is removed, a single bandage is placed over the incision.
The CIPI ™ procedure's administration method allows for more accurate targeting of the cancerous tumors while potentially avoiding the damage an invasive surgery can cause. Furthermore, by vastly reducing the damage caused to the body, CIPI ™ may reduce the recovery time and negative impact that surgery has on the immune system.
A unique benefit to the CIPI ™ procedure is its ability to circumvent the pancreas' protective stroma, which acts as a protective barrier, through direct injection of ICCA's genetically targeted medications into the tumors. The procedure utilizes catheter delivery which helps to maximize absorption of personalized medications into the targeted tumor, not only working to improve the effect these customized medications can have on the tumor, but also possibly aiding in reducing the negative side-effects chemotherapy can have on healthy cells.
Customization of Pancreatic Cancer Treatment Selection
From there ICCA uses its unique process to build a personalized treatment protocol that utilizes this information to treat advanced pancreatic cancer on multiple levels. Through our partner, Vertisis Custom Pharmacy, we are able to build customized medications that are unique and specialized. Because we work so closely with Vertisis we can personalize our medications to be completely customized for our patients' needs.
At ICCA we are looking to provide a comprehensive approach to treating advanced pancreatic cancer and we will use every tool at our disposal to try and build the most effective treatment plan to help our patients outperform. CIPI ™ is designed to treat the fibrous and stubborn solid tumors that are associated with pancreatic cancer but since most patients will have an advanced pancreatic cancer prognosis, they may need much more than CIPI ™ to treat their disease. The majority of pancreatic cancer patients will receive a late-stage diagnosis which will lead to an aggressive form of cancer that has progressed to other parts of the body like the liver. When pancreatic cancer has spread to the liver or other parts of the body ICCA is going to look to supplemental treatment options.
Genetically Targeted Fractionated Chemotherapy for Pancreatic Cancer
Genetically Targeted Fractionated Chemotherapy (GTFC ™) may be used in combination with CIPI ™ to treat the metastasized cancer in addition to the circulating cancer cells that are flowing through the body . GTFC ™ is a unique treatment program used only by ICCA that utilizes in-depth genetic targeting and micro-dosed chemotherapies to provide a treatment that can hit more biomarker targets than normal cancer treatment while providing the possibility of reduced negative side-effects . GTFC ™ is the culmination of ICCA's nearly twenty years of experience treating late-stage and complex cancer and we believe the combination of treatments helps to gives our patients a greater chance to progress difficult and metastasized cancers.
At Integrative Cancer Centers of America we are very excited about the CIPI ™ procedure. We truly believe that CIPI ™ in combination with GTFC ™ may be able to substantially help patients with advanced pancreatic cancer. It has always been our mission at ICCA to provide our patients with the highest quality and most advanced care possible so we can help them progress and achieve a better quality of life and CIPI ™ represents another step in that process. We continue to strive to bring the future of medicine to our patients because we believe all cancer patients deserve the chance to receive the best possible care our society has to offer. If you or your loved one has been diagnosed with pancreatic cancer, please don't hesitate to contact us at (888) 526-6398. You and your family deserve a higher level of care and compassion. May God bless you on your journey to healing!
Consult with your doctor to see if CIPI ™ is right for you. Not every patient is a candidate for Chemo Immunotherapy Percutaneous Injection. Some cancers may not have actionable biomarkers or molecular profiles. Do not alter your medical care based on any information provided in this article. Please, consult your doctor prior to changing or stopping any current medical treatment you are receiving.
 Pancreatic cancer prognosis. [cited 2019 6/21]; Available from: http://pancreatic.org/
 Smith, A.J., J. Oertle, and D.J.J.o.C.T. Prato, Genetically Targeted Fractionated Chemotherapy. 2015. 6(02): p. 182.